J & J raises annual profit forecast on anti-inflammatory drug demand

Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit. Investors are focused on how Johnson & Johnson, now a standalone pharmaceutical and medical…#johnsonjohnson

Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news